Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
18 Maio 2023 - 8:00AM
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage
biopharmaceutical company advancing targeted protein degradation
(TPD) to deliver novel small molecule protein degrader medicines,
today presented positive Phase 1 clinical data from its lead
program, KT-474 (SAR444656), a potent, highly selective, orally
bioavailable IRAK4 degrader. The Company delivered an oral
presentation at the European Academy of Dermatology and Venereology
(EADV) Symposium, taking place from May 18-20, 2023, in Seville,
Spain.
IRAK4 is a key protein involved in inflammation mediated by the
activation of toll-like receptors (TLRs) and IL-1 receptors
(IL-1Rs). Aberrant activation of these pathways is the underlying
cause of multiple immune-inflammatory conditions. KT-474, a
potential first-in-class IRAK4 degrader, is in development for the
treatment of TLR/IL-1R-driven immune-inflammatory diseases with
high unmet medical need, such as hidradenitis suppurativa (HS),
atopic dermatitis (AD), and potentially others. KT-474 is designed
to block TLR/IL-1R-mediated inflammation more broadly compared to
monoclonal antibodies targeting single cytokines, and to enable
pathway inhibition that is superior to IRAK4 kinase inhibitors by
abolishing both the kinase and scaffolding functions of IRAK4,
thereby providing a novel therapeutic approach.
The data demonstrated that KT-474 administered to HS and AD
patients had safety, PK and PD similar to healthy volunteers,
achieved robust IRAK4 degradation in blood and skin associated with
a systemic anti-inflammatory effect, and showed promising clinical
activity in HS and AD. The Company previously reported on the full
data set in December, and today’s presentation marks the first time
these results have been shared at a major scientific meeting.
“The KT-474 Phase 1 trial was a substantial accomplishment for
Kymera, showcasing the high fidelity of PK/PD and safety
translation from preclinical species to humans for our
heterobifunctional degrader platform. KT-474 exhibited clinical
activity in HS and AD patients that we believe is superior to IRAK4
small molecule kinase inhibitors and appears competitive with
standard of care biologics and other agents in development in both
HS and AD,” said Jared Gollob, M.D., Chief Medical Officer at
Kymera Therapeutics. “These results validate IRAK4 degradation as a
potential best-in-class mechanism in TLR/IL-1R-driven inflammatory
diseases that has the potential to improve the lives of patients
with conditions like HS and AD and potentially other indications.
We look forward to sharing additional updates as our partner Sanofi
initiates Phase 2 clinical trials of KT-474 in HS and AD, with the
first study in HS planned for initiation in 2023.”
Presentation at EADVTitle: Safety and Efficacy
of IRAK4 Degrader KT-474 (SAR444656) for Hidradenitis Suppurativa
and Atopic DermatitisPresentation ID: FC02.05Session Time: 11:45 –
12:00 PM CEST, May 18, 2023 Location: Auditorium 3Presenter: Jared
Gollob, M.D., Chief Medical Officer, Kymera Therapeutics
About Kymera TherapeuticsKymera is a
biopharmaceutical company pioneering the field of targeted protein
degradation, a transformative approach to address disease targets
and pathways inaccessible with conventional therapeutics. Kymera’s
Pegasus platform is a powerful drug discovery engine, advancing
novel small molecule programs designed to harness the body’s innate
protein recycling machinery to degrade dysregulated,
disease-causing proteins. With a focus on undrugged nodes in
validated pathways, Kymera is advancing a pipeline of novel
therapeutic candidates designed to address the most promising
targets and provide patients with more effective treatments.
Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within
the IL-1R/TLR or JAK/STAT pathways, and the MDM2 oncoprotein,
providing the opportunity to treat patients with a broad range of
immune-inflammatory diseases, hematologic malignancies, and solid
tumors.
Founded in 2016, Kymera is headquartered in Watertown, Mass.
Kymera has been named a “Fierce 15” company by Fierce Biotech and
has been recognized by both the Boston Globe and the Boston
Business Journal as one of Boston’s top workplaces. For more
information about our people, science, and pipeline, please visit
www.kymeratx.com or follow us on Twitter or LinkedIn.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, without limitation,
implied and express statements by Kymera Therapeutics regarding
its: strategy, business plans and objectives for the IRAK4,
IRAKIMiD, STAT3 and MDM2 degrader programs; plans and timelines for
the preclinical and clinical development of its product candidates,
including the therapeutic potential, clinical benefits and safety
thereof; expectations regarding timing, success and data
announcements of current ongoing preclinical and clinical trials;
the ability to initiate new clinical programs; and Kymera’s
financial condition and expected cash runway into the second half
of 2025. The words "may," “might,” "will," "could," "would,"
"should," "expect," "plan," "anticipate," "intend," "believe,"
“expect,” "estimate," “seek,” "predict," “future,” "project,"
"potential," "continue," "target" and similar words or expressions
are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, risks associated
with: the impact of COVID-19 on countries or regions in which we
have operations or do business, as well as on the timing and
anticipated results of our current and future preclinical studies
and clinical trials, supply chain, strategy and future operations;
the delay of any current and future preclinical studies or clinical
trials or the development of Kymera Therapeutics' drug candidates;
the risk that the results of current preclinical studies and
clinical trials may not be predictive of future results in
connection with current or future preclinical and clinical trials,
including those for KT-474, KT-333, KT-413 and KT-253; Kymera
Therapeutics' ability to successfully demonstrate the safety and
efficacy of its drug candidates; the timing and outcome of the
Kymera Therapeutics' planned interactions with regulatory
authorities; obtaining, maintaining and protecting its intellectual
property; and Kymera Therapeutics' relationships with its existing
and future collaboration partners. These and other risks and
uncertainties are described in greater detail in the section
entitled "Risk Factors" in the Annual Report on Form 10-K for the
year ended December 31, 2022 filed on February 23, 2023, as well as
discussions of potential risks, uncertainties, and other important
factors in Kymera Therapeutics' subsequent filings with the
Securities and Exchange Commission. In addition, any
forward-looking statements represent Kymera Therapeutics' views
only as of today and should not be relied upon as representing its
views as of any subsequent date. Kymera Therapeutics explicitly
disclaims any obligation to update any forward-looking statements.
No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking statements.
Investor
Contact: Bruce Jacobs Chief Financial
Officer investors@kymeratx.com 857-285-5300 Chris
Brinzey Managing Director,
Westwicke chris.brinzey@westwicke.com 339-970-2843 |
Media
Contact: Todd Cooper Senior Vice President,
Corporate
Affairs media@kymeratx.com 857-285-5300 |
Kymera Therapeutics (NASDAQ:KYMR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Kymera Therapeutics (NASDAQ:KYMR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024